Greg Jennings LLC Makes New Investment in AbbVie Inc. $ABBV

Key Points

• Greg Jennings LLC acquired 27,954 AbbVie shares worth approximately $7.3 million in the third quarter, making ABBV 4.9% of its portfolio and its eighth-largest holding. Institutional investors collectively own 70.23% of the stock.
• AbbVie reported quarterly EPS of $3.65 and revenue of $16.99 billion, exceeding analyst estimates, while revenue increased 10.2% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $277.18.
• The company’s pipeline provided positive catalysts, as investigational ABBV-466 outperformed monotherapies in a Crohn’s disease study and AbbVie prepared to present data from seven oncology assets. AbbVie also declared a quarterly dividend of $1.73 per share, equivalent to a 2.4% annual yield.

Greg Jennings LLC acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 27,954 shares of the company's stock, valued at approximately $7,313,000. AbbVie makes up 4.9% of Greg Jennings LLC's portfolio, making the stock its 8th largest position.

A number of other hedge funds have also recently bought and sold shares of ABBV. Lifelong Wealth Advisors Inc. raised its holdings in shares of AbbVie by 2.1% in the third quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company's stock valued at $459,000 after purchasing an additional 36 shares during the last quarter. James T. Borello RIA lifted its position in shares of AbbVie by 3.5% during the third quarter. James T. Borello RIA now owns 1,192 shares of the company's stock valued at $312,000 after purchasing an additional 40 shares in the last quarter. ACT Advisors LLC. lifted its position in shares of AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock valued at $425,000 after purchasing an additional 41 shares in the last quarter. Willner & Heller LLC boosted its holdings in AbbVie by 0.7% during the second quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock worth $1,472,000 after purchasing an additional 43 shares during the last quarter. Finally, B.O.S.S. Retirement Advisors LLC boosted its holdings in AbbVie by 3.1% during the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock worth $359,000 after purchasing an additional 43 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s investigational ABBV-466, which targets both IL-23 p19 and integrin α4β7, produced higher endoscopic remission rates in moderate-to-severe Crohn’s disease than either monotherapy at Week 12. The treatment advantage widened by Week 24, while biomarker analyses indicated intestinal tissue repair and barrier restoration. The results improve the drug’s potential as a differentiated next-generation immunology product. AbbVie ABBV-466 Crohn’s disease data
• Positive Sentiment: Analysts viewed the Crohn’s findings favorably because ABBV-466 outperformed AbbVie’s established blockbuster Skyrizi in a mid-stage comparison, highlighting the company’s strategy of combining complementary immune mechanisms. The data could help extend AbbVie’s leadership in inflammatory diseases if confirmed in later-stage trials. AbbVie Crohn’s combination beats Skyrizi
• Positive Sentiment: AbbVie announced its largest-ever presence at the 2026 ESMO Congress, with data from seven oncology assets spanning lung, colorectal, ovarian, prostate and gastric cancers. Updates on antibody-drug conjugates, precision medicines, Elahere and other programs could provide additional pipeline catalysts when presented October 23–27. AbbVie 2026 ESMO oncology data
• Neutral Sentiment: Investors are also watching AbbVie’s neuroscience franchise ahead of quarterly results. Analysts anticipate roughly 16% third-quarter revenue growth from established therapies and newer Parkinson’s treatments, but the outlook will depend on the company’s upcoming earnings report. AbbVie neuroscience franchise outlook

AbbVie Price Performance

Shares of AbbVie stock opened at $282.95 on Tuesday. AbbVie Inc. has a 1 year low of $190.75 and a 1 year high of $291.40. The firm has a market cap of $499.91 billion, a PE ratio of 79.93, a P/E/G ratio of 1.30 and a beta of 0.24. The stock has a fifty day moving average price of $263.44 and a 200-day moving average price of $239.87.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts anticipate that AbbVie Inc. will post 13.94 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie's dividend payout ratio (DPR) is 195.48%.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company's stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ABBV shares. Rothschild & Co Redburn upped their price objective on shares of AbbVie from $284.00 to $285.00 and gave the stock a "buy" rating in a research report on Tuesday, August 4th. Wolfe Research upgraded shares of AbbVie from a "peer perform" rating to an "outperform" rating and increased their price objective for the company from $235.00 to $300.00 in a research note on Thursday, August 13th. BNP Paribas Exane lifted their target price on shares of AbbVie from $218.00 to $247.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 11th. Argus boosted their target price on AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Finally, Sanford C. Bernstein restated a "market perform" rating and issued a $225.00 target price (up from $203.00) on shares of AbbVie in a research note on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $277.18.

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.